Back to News
Market Impact: 0.25
UK Revokes Marketing Authorisation For Valneva's Chikungunya Vaccine IXCHIQ; Shares Slide
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Valneva said the UK Commission on Human Medicines conducted a further benefit-risk assessment of IXCHIQ for travellers. The article fragment says the MHRA revoked something, but cuts off before specifying what was revoked; no further details or market reaction are provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
VALN-0.70
More News
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- Why is the Chinese stock market missing the AI rally
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- ‘Piece by piece’: Trump administration vows to dismantle the International Criminal Court with sweeping new sanctions
- Why is T-Mobile stock tumbling today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Financial Research Benchmarks: What the Scores Mean
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper